ALXO - Potential Pre - Run-Up into Phase 1b/2 Confernce
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
12/12/2024 ET
Phase 1b/2 presentation due at December 12, 2024. Phase 1b/2 first patient dosed, October 5, 2021.
Drug:
Zanidatamab and Evorpacept (ALX148)
HER2 Breast cancer and solid tumors
Strategy:
We may observe a slight pre-run-up leading into the presentation. If your position is in profit by that point, it’s wise to secure gains by taking at least partial profits, as the presentation’s outcome is highly speculative.
Key Insights on ALXO:
ALXO has a robust pipeline, presenting promising growth potential.
Key catalysts are expected by mid-2025, which could significantly impact the company’s valuation.
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$1.80
Resistance Point:
$1.95
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Risk/Money Management
Take Profit (TP): Set a target at $2.20
Stop Loss (SL): Set at under $1.50 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
- Float: 30.437M
- Short % of Float: 23.74%
12/12/2024 ET
Phase 1b/2 presentation due at December 12, 2024. Phase 1b/2 first patient dosed, October 5, 2021.
Drug:
Zanidatamab and Evorpacept (ALX148)
HER2 Breast cancer and solid tumors
Strategy:
We may observe a slight pre-run-up leading into the presentation. If your position is in profit by that point, it’s wise to secure gains by taking at least partial profits, as the presentation’s outcome is highly speculative.
Key Insights on ALXO:
ALXO has a robust pipeline, presenting promising growth potential.
Key catalysts are expected by mid-2025, which could significantly impact the company’s valuation.
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$1.80
Resistance Point:
$1.95
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Risk/Money Management
Take Profit (TP): Set a target at $2.20
Stop Loss (SL): Set at under $1.50 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.